Ibrutinib Deacryloylpiperidine CAS 330786-24-8 Purity >99.0% (HPLC)

Short Description:

Chemical Name: Ibrutinib Deacryloylpiperidine

CAS: 330786-24-8

Purity: >99.0% (HPLC)

Appearance: Off-White to Khaki Powder

Intermediate of Ibrutinib (CAS: 936563-96-1)

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Chemical Properties:

Chemical Name	3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Synonyms	Ibrutinib intermeidate N-2; Ibrutinib Deacryloylpiperidine; Ibrutinib Impurity 8; 5-(4-Phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine; IBT4A; Ibrutinib N-Despiperidinyl Impurity
CAS Number	330786-24-8
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C17H13N5O
Molecular Weight	303.32
Melting Point	>262℃(dec.)
Density	1.380±0.06 g/cm3
Hazard Class	6.1; Poison
Packing Group	III
COA & MSDS	Available
Origin	Shanghai, China
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Off-White to Khaki Powder
Identification	HNMR, LC-MS
Purity / Analysis Method	>99.0% (HPLC)
Loss on Drying	<1.00%
Single Max. Impurity	<1.00%
Total Impurities	<1.00%
Heavy Metals (as Pb)	<20ppm
Test Standard	Enterprise Standard
Usage	Intermediate of Ibrutinib (CAS: 936563-96-1)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

330786-24-8 - Application:

3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (CAS: 330786-24-8) is a useful synthetic intermediate in the synthesis of Ibrutinib (CAS: 936563-96-1). Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). MCL and CLL are belonged to the B-cell non-Hodgkin's lymphoma, which is difficult to cure and easy to recurrent. Common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. Ibrutinib and B lymphocytes could target with BTK which is necessary for formation, differentiation, and transmission of information, inhibit BTK activity irreversibly, and inhibit tumor cell proliferation and survival effectively. Ibrutinib could be rapidly absorbed after oral administration, during 1~2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, Ibrutinib will become a new choice of treatment of CLL and MCL.